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Objective: To investigate whether aromatase expression in the eutopic endometrium correlates 
with the presence and severity of endometriosis in patients with infertility and/or dysmenorrhea 
undergoing laparoscopy and hysteroscopy.
Patients: The study involved 106 patients of reproductive age with symptoms of   dysmenorrhea 
and infertility. Sixteen endometriosis-free asymptomatic patients were used as a control 
group.
Methods: Concomitant laparoscopy and hysteroscopy was carried out in all cases. An 
  endometrial biopsy was taken to determine aromatase p450 expression by immunohistochemistry. 
Endometriosis was staged according to the American Society of Reproductive Medicine 
classification.
Results: Endometriosis was diagnosed by laparoscopy in 92/106 symptomatic patients. In 
this group, aromatase expression was detected in the eutopic endometrium of 66/92 patients 
with endometriosis (72%) and in 13/14 (95%) patients in the symptomatic, endometriosis-free 
group (P = 0.09). Aromatase expression was not detected in any patients from the control group. 
In the endometriosis group, aromatase expression was detected in the eutopic endometrium of 
28/45 patients (62%) with American Society of Reproductive Medicine classification stage 
1 of the disease, in 11/14 patients (78%) with stage II, 14/20 patients (70%) with stage III, and 
in 12/13 patients (92%) with stage IV; however, the difference was only statistically significant 
between stages I and IV (P = 0.04).
Conclusion: Aromatase expression in the endometrium was associated with the presence of 
dysmenorrhea and infertility irrespective of the presence of endometriosis. When endometriosis 
was present, however, there was a tendency for aromatase expression to be positively correlated 
with dysmenorrhea severity.
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Introduction
The onset of clinical symptoms associated with endometriosis may predate cli  nical 
diagnosis by many years.1 Although this may simply reflect a lack of sensitive, non-
invasive methods capable of diagnosing this pathology at an early stage, it is also 
possible that the enzymatic and inflammatory changes that signal the development of 
endometriosis may be initiated in the endometrium before the disease is established in 
the pelvis. These functional changes may involve the upregulation of enzymes related 
to estrogen synthesis that are overexpressed in the eutopic endometrium of patients with 
endometriosis, where they may play a pivotal role not only in the implantation failure 
associated with this pathology but also in the onset of menstrual symptoms.2–4
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It is known that both endometriotic lesions and the 
eutopic endometrium are able to express aromatase, a key 
enzyme in the transformation of androgens into estrogens. 
The release of these enzymes is stimulated by in  flammatory 
mediators such as the prostaglandins produced by the action 
of cyclooxygenase-2 (Cox-2).2,3 The aggressiveness of 
endometriosis appears to correlate with the intensity of the 
expression of this enzyme in lesions, with the most aggres-
sive occurring in red peritoneal lesions.2 A correlation was 
also found between the severity of endometriosis and the 
intensity of Cox-2 expression in both lesions and the eutopic 
endometrium, thus suggesting a role of locally produced 
estrogens in the upregulation of this enzyme.3–5
Nevertheless, the role played by aromatase and 
Cox-2 expression in the eutopic endometrium in relation 
to the development of endometriosis and in the intensity of 
menstrual-related symptoms is not totally understood. It was 
recently suggested that endometriosis may commence as an 
endometrial disease provoked by the aberrant expression of 
aromatase in this tissue, as this appears to play a pivotal role 
in its survival in ectopic locations.4 Gene array studies have 
shown that the expression profiles of endometriosis lesions 
and the eutopic endometrium are similar, which supports 
the hypothesis that endometriosis is an endometrial disease.6 
It is biologically plausible that the presence of aromatase 
activity in the endometrium is pivotal for the development 
of endometriosis by blocking phagocytosis by activated mac-
rophages and may also be responsible for the exacerbation 
of menstrual symptoms whose onset predates the diagnosis 
of this pathology.1,4,7 In this hypothesis, endometriosis would 
be a late consequence of enzymatic changes that occur in the 
endometrium prior to its establishment outside the uterus, 
which could explain the lag that is often reported between the 
onset of symptoms and diagnosis of the disease.
This hypothesis could be tested by examining patients 
with severe dysmenorrhea or infertility to determine whether 
laparoscopy reveals endometriosis despite aromatase 
expression already being positive in the endometrium. In 
the present study, aromatase expression was determined in 
the eutopic endometrium of patients with severe menstrual 
symptoms and/or infertility who underwent laparoscopy and 
hys  teroscopy as a part of their diagnostic work-up.
Methods
A total of 106 patients of reproductive age (range = 18–47 years) 
received a laparoscopy and hysteroscopy with endometrial 
biopsy that was carried out using a 4 mm Karman curette 
attached to a 10 mL syringe to produce a vacuum, which is 
the standard procedure for the evaluation of menorrhagia, 
severe dysmenorrhea, or infertility in the day hospital where 
the current study was carried out. All patients included in 
this group had reported at least two of these three symptoms 
for periods ranging from 2 to 8 years. The control group 
consisted of sixteen patients who received a laparoscopy 
for reasons unrelated to infertility or severe dysmenorrhea 
and who were found to be endometriosis-free during the 
examination. The indications for laparoscopy in this group 
were either benign non-endometriotic ovarian cysts (seven 
patients) or tubal ligation (nine patients). In these patients, 
an endometrial biopsy was performed at the time of the 
laparoscopy using a 4 mm Karman curette.
The patients enrolled in the study gave written informed 
consent for immunohistochemical studies to be carried out 
on the endometrial biopsy specimens obtained as part of 
their standard medical care. This study was approved by the 
institution’s internal review board.
Laparoscopies were performed either during the prolif-
erative phase (n = 72) or in the secretory or menstrual phase 
(n = 34), since the timing of the procedure depended on the 
availability of the surgical theater and the specifics of the 
institution’s waiting list. The laparoscopy reports and color 
images were retained in the patients’ files for further evaluation 
if necessary. During the laparoscopy procedure, the surgical 
team ascertained the presence of endome  triosis and graded 
the stage of the disease in accordance with the American 
Society of Reproductive Medicine (ASRM)   classification.8 
Using laparoscopic classification criteria, the patients with 
endometriosis were divided into four groups according to 
the severity of their lesions, using the ASRM classification 
of minimal (stage I), mild (stage II), moderate (stage III), or 
severe (stage IV). The severity of menstrual symptoms such as 
dysmenorrhea, the presence or absence of infertility, and the 
reason for laparoscopy were recorded in the patients’ files.
Endometrial samples were fixed in 10% formalin before 
being assessed. Immunohistochemistry was performed fol-
lowing antigen retrieval to detect the presence of aromatase 
p450. Aromatase expression was investigated using the 
commercially available monoclonal antibody MCA2077 
clone H4 (Serotech, Raleigh, NC). Antigen retrieval was 
performed using Tris-EDTA buffer (pH 8.0; Sigma-Aldrich, 
São Paulo, Brazil). The reaction was revealed using the 
streptavidin-biotin method. The presence of aromatase 
expression was rated as positive if there was any detect-
able staining reaction in the glandular epithelium or nega-
tive when no reaction was observed. Placental tissue and 
an atrophic endometrial sample were used as positive 
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and negative controls, respectively, in all immunostaining 
reactions for aromatase p450. Statistical analysis was per-
formed using the one-tailed chi-square test for differences in 
percentages, using an unnamed online interactive calculation 
tool for chi-square tests of goodness of fit and independence, 
which is hosted at http://quantpsy.org. Results were consid-
ered statistically significant at P , 0.05.
Results
In the group of patients with severe dysmenorrhea, 
  endometriosis was diagnosed in 90/106 patients. In the 
remaining 16 cases, the pelvis was found to be normal   during 
the laparoscopy.
Aromatase expression in the eutopic endometrium was 
detected by immunohistochemistry mainly in the glandular 
epithelium (Figure 1). The staining reaction was positive 
in 66/92 patients (72%) with endometriosis and symptoms 
of dysmenorrhea and/or infertility, and there were no 
s  ignificant differences between the phases of the patient’s 
menstrual cycle. In symptomatic patients who were found 
to have normal pelvic results during the laparoscopy, 
a  romatase expression was still positive in the endometrium in 
13/14 cases (95%), though this difference was not statistically 
significant (P = 0.09). In the asymptomatic control group 
without endometriosis, however, aromatase expression was 
negative in the eutopic endometrium in all cases.
In the subset of symptomatic patients with a laparoscopic 
diagnosis of endometriosis, the percentage of endometrial 
samples positively expressing aromatase in the glandular 
epithelium showed a trend toward greater positivity as 
the severity of the disease increased in accordance with 
the ASRM criteria. Aromatase expression was detected 
in the eutopic endometrium of 28/45 patients with stage I 
  endometriosis (62%), 11/14 patients with stage II (78%), 
14/20 patients with stage III (70%) and 12/13 patients with 
stage IV endometriosis (92%). However, only the dif  ference 
between stages I and IV of the disease was statistically 
si  gnificant (P = 0.04) (Table 1).
Discussion
The present study not only showed an association between the 
presence of aromatase expression in the eutopic en  dometrium 
and the severity of endometriosis lesions at laparoscopy but 
also suggests that this expression was already present in 
symptomatic patients in whom pelvic endometriosis was 
not found. These findings agree with the hypothesis that 
endometriosis may commence as an endometrial disease 
resulting from functional changes in the endometrium before 
the disease establishes outside the uterus.
The presence of similar epigenetic changes in the eutopic 
endometrium and the endometriotic lesions further corrobo-
rates the hypothesis that endometriosis is an endometrial 
disease.6 The positive correlation between mRNA levels in 
the eutopic endometrium and the severity of en  dometriosis 
and adenomyosis also supports this   hypothesis.9 Whether 
endometriosis starts as an endometrial disease before estab-
lishing itself elsewhere in the pelvis6,7 cannot be proven by 
the present study, but previous work shows that the onset 
of symptoms associated with this pathology may com-
mence many years prior to its diagnosis, which support this 
  hypothesis.1 The occurrence of severe dysmenorrhea for 
many years prior to a diagnosis of endometriosis may reflect 
these initial endometrial changes favoring the upregulation of 
both estradiol and prostaglandin production in this tissue.4,6,7 
The occurrence of such symptoms in patients with a normal 
pelvis at laparoscopy, as shown in the present study, may 
suggest that these functional changes in the endometrium are 
not only associated with the onset of endometriosis-related 
symptoms but that they may occur prior to the diagnosis of 
any pelvic pathology by laparoscopy. Functional en  dometrial 
changes leading to an increase in aromatase expression 
Figure  1  Aromatase  expression  in  the  eutopic  endometrium  detected  by 
immunohistochemistry.
Table 1 Aromatase expression in the eutopic endometrium and 
the laparoscopic classification of endometriotic lesions according 
to American Society of Reproductive Medicine classification
Type of lesion Aromatase positive
Stage I 28/45 (62%)
Stage II 11/14 (78%)
Stage III 14/20 (70%)
Stage IV 12/13 (92%)
Notes: Chi-square test: stages I and IV, P , 0.05. The other differences were not 
statistically significant.
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may therefore predate the development of endometriosis, 
initially provoking dysmenorrhea and possibly infertility 
before triggering the development of the disease outside the 
uterus.4 It still remains to be determined whether this group 
of symptomatic patients represents a high-risk population 
for the development of endometriosis. In patients with an 
established diagnosis of endometriosis, however, endometrial 
positivity for aromatase tends to increase with the severity 
of the disease. This may be due to the greater possibility of 
spontaneous regression of early stage endometriosis, which 
may occur because of reduced aromatase activity in the 
eutopic endometrium.
Although aromatase expression in the eutopic e  ndometrium 
may be pivotal for the onset and progression of endometriosis, 
it has yet to be clarified how this enzyme affects the devel-
opment of endometriosis. The role played by estrogens in 
inhibiting immune surveillance by activated macrophages has 
been suggested as one of the likely mechanisms by which 
aromatase affects the course of endometriosis.4,7,10 This local 
estrogen production in the endometrial cells shed to the pelvis 
in retrograde menstruation may favor their   survival in these 
ectopic locations by directly preventing their destruction 
by activated immune cells through the inhibition of the 
  phagocytosis mechanism.10–13
The presence of aromatase in the eutopic endometrium 
may therefore represent the initial step in the development 
of endometriosis and could be necessary for the develop-
ment of lesions outside the uterus.7 The similar genetic 
alterations found between endometriotic lesions and the 
respective eutopic endometrium also indicate a common 
histological origin.7
The current study’s finding that aromatase expression 
is detectable by immunohistochemistry in the   endometrium 
of symptomatic, endometriosis-free patients agrees with the 
hypothesis that this enzyme initially exacerbates   dysmenorrhea 
or causes infertility prior to facilitating the development of 
endometriosis elsewhere in the pelvis.   Nevertheless, a tempo-
ral relationship cannot be established solely from these data. 
A previous study has shown that aromatase expression in the 
endometrium reduces implantation rates in patients undergo-
ing in vitro fertilization, however, which may help to explain 
the lower fertility rate of women with endometriosis.14
The presence of aromatase and other enzymes related to 
estrogen metabolism in the eutopic endometrium will ultimately 
create a hyperestrogenic milieu, resulting in increased 
prostaglandin production, particularly because Cox-2 expression 
is upregulated by estradiol in this tissue.6–9,12,13 This would 
explain why the pelvis of a patient with severe dysmenorrhea 
or infertility may be normal, as was reported in the current 
study – aromatase expression in the eutopic endometrium may 
be sufficient to provoke these symptoms by enhancing the 
production of proinflammatory   prostaglandins in this tissue. 
However, the possibility that some of these endometriosis-free 
patients have adenomyosis cannot be completely excluded in 
this study, despite the fact that myometrial findings were normal 
at transvaginal sonography.
Estrogens produced locally in the endometriotic lesions 
and eutopic endometrium result in the mechanism of 
decreased immune surveillance and enhanced tolerance found 
in endometriosis,14 which may explain the inverse relationship 
between estrogen levels and impaired NK-cell function found 
as a function of the severity of the   disease.15 Local estrogen 
production would also stimulate the production of VEGF, 
growth factors, and inflammatory cytokines by immune 
cells, thus favoring the progression of endometriosis.12,15,16 
The blockade of phagocytosis by the local production of 
estrogens and the concomitant stimulation of growth and 
inflammatory factors would explain the   paradoxical effects 
of macrophages in endometriosis, which seem to interact 
with rather than destroy these ectopic endometrial cells, thus 
enhancing their growth and angiogenesis.12,17
In conclusion, a vicious cycle of enhanced inflammation 
and local estrogen production mediated by Cox-2 and aro-
matase expression in the eutopic endometrium of endometrio-
sis patients may play a pivotal role not only in determining 
the clinical course of this disease but also in defining the 
intensity of its debilitating symptoms. In the pelvic cavity, 
the ensuing inflammatory reaction provoked by the arrival 
of endometrial cells will further exacerbate their preexisting 
aromatase   activity, thus augmenting local estrogen production 
and halting phagocytosis by activated macrophages.6,7
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